Biomimetic
-
BioMimetic Therapeutics Completes Submission of PMA Application for FDA Approval of Augment™ Bone Graft
FRANKLIN, Tenn.–(BUSINESS WIRE)–BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced it has submitted the third and final module of its Premarket…
Read More » -
BioMimetic Therapeutics Strengthens its Agreement with Novartis for Exclusive Supply of rhPDGF-BB
BioMimetic Therapeutics Strengthens its Agreement with Novartis for Exclusive Supply of rhPDGF-BB 1/6/2010 4:10:00 PM ET Business Wire FRANKLIN, Tenn.–(BUSINESS WIRE)– BioMimetic…
Read More » -
BioMimetic Therapeutics Ships Augment™ Bone Graft to Canadian Distributor; Product Now Available for Sale to Canadian Customers
Franklin, Tenn. – December 11, 2009 – BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that the Company has shipped its…
Read More » -
BioMimetic Therapeutics Receives First Orthopedic Marketing Approval for Augment™ Bone Graft
FRANKLIN, Tenn.–(BUSINESS WIRE)–BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that it has received approval from Health Canada to begin the…
Read More »